PMID- 19378850
OWN - NLM
STAT- MEDLINE
DCOM- 20090514
LR  - 20090421
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 55
IP  - 3
DP  - 2009 Mar
TI  - [Prophylaxis and treatment of thromboembolism in oncology].
PG  - 219-22
AB  - In this article, following guidelines for clinical practice are formulated. 1. 
      For patients undergoing cancer surgery, pharmacological thromboprophylaxis is 
      recommended. Low molecular weight heparins (LMWH), unfractionated heparin (UFH) 
      5,000 U three times daily, or fondaparinux are recommended; in the Czech 
      Republic, LMWH are most frequently used. For patients undergoing major cancer 
      surgery extended prophylaxis for 4 weeks is recommended. For patients with a high 
      risk of bleeding, intermittent pneumatic compression presents a reasonable 
      alternative. 2. For cancer patients, who are bedridden, or hospitalized with an 
      acute illness, thromboprophylaxis with LMWH is recommended. Patients with 
      multiple myeloma, undergoing induction therapy, including at least 2 thrombogenic 
      drugs (thalidomide, lenalidomide, dexamethasone, prednison, and anthracyclines) 
      should be treated with LMWH. In other cancer patients, pharmacological 
      thromboprophylaxis is not generally recommended, however, its application should 
      be considered namely in patients with a history of venous thromboembolism (VTE), 
      or in the presence of multiple risk factors. The cancer patients with VTE should 
      be treated with LMWH for the first 6 months; the initial dose being 200 IU/kg 
      daily, this can be reduced to 2/3-3/4 after one month. The therapy should be 
      reevaluated after 6 month and subsequent therapy using LMWH or warfarin is 
      recommended indefinitely, unless the cancer is resolved or any major 
      contraindications arise.
FAU - Kessler, P
AU  - Kessler P
AD  - Oddeleni hematologie a transfuziologie Nemocnice Pelhrimov. 
      pkessler@hospital-pe.cz
LA  - cze
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Profylaxe a lecba tromboembolicke nemoci v onkologii.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
SB  - IM
MH  - Humans
MH  - Neoplasms/complications/*surgery
MH  - Postoperative Complications/*prevention & control
MH  - Thromboembolism/drug therapy/etiology/*prevention & control
RF  - 36
EDAT- 2009/04/22 09:00
MHDA- 2009/05/15 09:00
CRDT- 2009/04/22 09:00
PHST- 2009/04/22 09:00 [entrez]
PHST- 2009/04/22 09:00 [pubmed]
PHST- 2009/05/15 09:00 [medline]
PST - ppublish
SO  - Vnitr Lek. 2009 Mar;55(3):219-22.